Fluor Corp. (FLR) Pops 3.23% for February 16

Equities Staff |

One of the S&P 500’s big winners for Tuesday February 16 was Fluor Corp. (FLR) as the company’s stock climbed 3.23% to $45.05 on volume of 1.23 million shares.

The stock opened at $44.28 and saw an intraday low of $43.79 and an intraday high of $45.17. All told, the day saw a per-share gain of $1.41. The stock’s average daily volume of 1.69 million and 141.61 million shares outstanding. Fluor Corp. now has a 50-day SMA is $44.88 and 200-day SMA is $48.32, and it has a 52-week high of $62.26 and a 52-week low of $39.48.

Fluor Corp through its subsidiaries engages in professional services providing engineering, procurement, construction and maintenance as well as project management services.

Based out of Irving, TX, Fluor Corp. has 37,508 employees and, after today’s trading, reached a market cap of $6.38 billion. The stock’s P/E Ratio is 9.3. Its P/S ratio is 0.45, P/B ratio is 2.08, and P/FCF ratio is 20.

For a complete fundamental analysis analysis of Fluor Corp., check out Equities.com’s Stock Valuation Analysis report for FLR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…